altretamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
141 645-05-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • altretamine
  • hexalen
  • hexamethylmelamine
  • hexylen
The precise mechanism by which altretamine capsules exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine capsules resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of altretamine capsules and its metabolites have been negative. Altretamine capsules has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement for cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and in vivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown.
  • Molecular weight: 210.29
  • Formula: C9H18N6
  • CLOGP: 1.66
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 48.39
  • ALOGS: -1.83
  • ROTB: 3

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 25.73 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
fu (Fraction unbound in plasma) 0.11 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
Dec. 26, 1990 FDA EISAI INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XX03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
MeSH PA D000477 Alkylating Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018906 Antineoplastic Agents, Alkylating
MeSH PA D009676 Noxae

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Malignant tumor of ovary indication 363443007 DOID:2394
Mood swings contraindication 18963009
Ataxia contraindication 20262006
Leukopenia contraindication 84828003 DOID:615
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Bone marrow depression contraindication 307762000
Vertigo contraindication 399153001
Breastfeeding (mother) contraindication 413712001
Unconscious contraindication 418107008
Severe Bone Marrow Depression contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.66 Basic
pKa2 3.04 Basic
pKa3 0.46 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cytochrome P450 1A2 Enzyme IC50 5.40 DRUG MATRIX

External reference:

IDSource
4019574 VUID
N0000147673 NUI
D02841 KEGG_DRUG
153474 RXNORM
C0019453 UMLSCUI
CHEBI:24564 CHEBI
CHEMBL1455 ChEMBL_ID
DB00488 DRUGBANK_ID
D006585 MESH_DESCRIPTOR_UI
2123 PUBCHEM_CID
7112 IUPHAR_LIGAND_ID
4825 INN_ID
Q8BIH59O7H UNII
4156 MMSL
759 MMSL
d01372 MMSL
387385000 SNOMEDCT_US
69879000 SNOMEDCT_US
4019574 VANDF
003567 NDDF

Pharmaceutical products:

None